Showing results (271-280 of 503) with videos related to

Sort By:
Pageof 51
Neurological Research|September 14, 2012
A technical approach to dissecting and assessing cadaveric veins pertinent to chronic cerebrospinal venous insufficiency in multiple sclerosisClaudiu I Diaconu, Susan M Staugaitis, Robert J Fox, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|June 2, 2018
Patient-Reported Disease-Modifying Therapy Adherence in the Clinic: A Reliable Metric?Devon S Conway, Maria Cecilia Vieira, Nicolas R Thompson, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 4, 2014
Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS)Ralf Gold, Gavin Giovannoni, J Theodore Phillips, et al.
Frontiers in Rehabilitation Sciences|October 3, 2022
Effects of exercise on sleep spindles in Parkinson's diseaseAdeel Ali Memon, Corina Catiul, Zachary Irwin, et al.
Plos One|February 23, 2011
Chronic cerebrospinal vascular insufficiency is not associated with HLA DRB1*1501 status in multiple sclerosis patientsBianca Weinstock-Guttman, Robert Zivadinov, Gary Cutter, et al.
Academic Radiology|September 14, 2024
Improving the Assessment of Axonal Injury in Early Multiple SclerosisAhmad A Toubasi, Gary Cutter, Caroline Gheen, et al.
Journal of Magnetic Resonance Imaging : JMRI|December 10, 2024
Improving the Detection of Myelin Integrity in Multiple Sclerosis Using Selective Inversion Recovery for MRI With Quantitative Magnetization TransferAhmad A Toubasi, Dhairya A Lakhani, Gary Cutter, et al.
BMJ Open|December 4, 2012
Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b studyDouglas S Goodin, George C Ebers, Gary Cutter, et al.
Archives of Neurology|September 10, 2008
Reproducibility of optical coherence tomography in multiple sclerosisDeanna Cettomai, Mathew Pulicken, Eliza Gordon-Lipkin, et al.
Lancet (London, England)|February 11, 2014
EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trialAndrew S C Rice, Robert H Dworkin, Tom D McCarthy, et al.
Pageof 51